177 related articles for article (PubMed ID: 15208643)
21. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia.
Steinbach D; Sell W; Voigt A; Hermann J; Zintl F; Sauerbrey A
Leukemia; 2002 Aug; 16(8):1443-7. PubMed ID: 12145683
[TBL] [Abstract][Full Text] [Related]
22. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
Kowalski P; Stein U; Scheffer GL; Lage H
Cancer Gene Ther; 2002 Jul; 9(7):579-86. PubMed ID: 12082458
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer resistance protein (BCRP) in acute leukemia.
Plasschaert SL; Van Der Kolk DM; De Bont ES; Vellenga E; Kamps WA; De Vries EG
Leuk Lymphoma; 2004 Apr; 45(4):649-54. PubMed ID: 15160935
[TBL] [Abstract][Full Text] [Related]
24. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.
van der Pol MA; Broxterman HJ; Pater JM; Feller N; van der Maas M; Weijers GW; Scheffer GL; Allen JD; Scheper RJ; van Loevezijn A; Ossenkoppele GJ; Schuurhuis GJ
Haematologica; 2003 Feb; 88(2):134-47. PubMed ID: 12604403
[TBL] [Abstract][Full Text] [Related]
25. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.
Huls M; Brown CD; Windass AS; Sayer R; van den Heuvel JJ; Heemskerk S; Russel FG; Masereeuw R
Kidney Int; 2008 Jan; 73(2):220-5. PubMed ID: 17978814
[TBL] [Abstract][Full Text] [Related]
26. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).
Robey RW; Honjo Y; van de Laar A; Miyake K; Regis JT; Litman T; Bates SE
Biochim Biophys Acta; 2001 Jun; 1512(2):171-82. PubMed ID: 11406094
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
28. Silencing the breast cancer resistance protein expression and function in caco-2 cells using lentiviral vector-based short hairpin RNA.
Zhang W; Li J; Allen SM; Weiskircher EA; Huang Y; George RA; Fong RG; Owen A; Hidalgo IJ
Drug Metab Dispos; 2009 Apr; 37(4):737-44. PubMed ID: 19131524
[TBL] [Abstract][Full Text] [Related]
29. Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.
Damiani D; Tiribelli M; Michelutti A; Geromin A; Cavallin M; Fabbro D; Pianta A; Malagola M; Damante G; Russo D; Fanin R
Leuk Res; 2010 Jul; 34(7):942-5. PubMed ID: 20122734
[TBL] [Abstract][Full Text] [Related]
30. BCRP mRNA expression v. clinical outcome in 40 adult AML patients.
Uggla B; Ståhl E; Wågsäter D; Paul C; Karlsson MG; Sirsjö A; Tidefelt U
Leuk Res; 2005 Feb; 29(2):141-6. PubMed ID: 15607361
[TBL] [Abstract][Full Text] [Related]
31. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
33. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia.
Benderra Z; Faussat AM; Sayada L; Perrot JY; Tang R; Chaoui D; Morjani H; Marzac C; Marie JP; Legrand O
Clin Cancer Res; 2005 Nov; 11(21):7764-72. PubMed ID: 16278398
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia.
Sargent JM; Williamson CJ; Maliepaard M; Elgie AW; Scheper RJ; Taylor CG
Br J Haematol; 2001 Nov; 115(2):257-62. PubMed ID: 11703319
[TBL] [Abstract][Full Text] [Related]
35. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2.
Kage K; Fujita T; Sugimoto Y
Cancer Sci; 2005 Dec; 96(12):866-72. PubMed ID: 16367905
[TBL] [Abstract][Full Text] [Related]
36. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Honjo Y; Hrycyna CA; Yan QW; Medina-Pérez WY; Robey RW; van de Laar A; Litman T; Dean M; Bates SE
Cancer Res; 2001 Sep; 61(18):6635-9. PubMed ID: 11559526
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Maliepaard M; van Gastelen MA; de Jong LA; Pluim D; van Waardenburg RC; Ruevekamp-Helmers MC; Floot BG; Schellens JH
Cancer Res; 1999 Sep; 59(18):4559-63. PubMed ID: 10493507
[TBL] [Abstract][Full Text] [Related]
38. [Drug-resistant proteins in breast cancer: recent progress in multidrug resistance].
Wu DL; Huang F; Lu HZ
Ai Zheng; 2003 Apr; 22(4):441-4. PubMed ID: 12704006
[TBL] [Abstract][Full Text] [Related]
39. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
40. [Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317].
Yuan JH; He ZM; Yu YH; Chen ZC
Ai Zheng; 2004 Oct; 23(10):1127-33. PubMed ID: 15473921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
